KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Amneal Pharmaceuticals (AMRX) Accumulated Depreciation & Amortization (2017 - 2025)

Amneal Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 9 years, most recently at $606.2 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 7.57% year-over-year to $606.2 million; the TTM value through Dec 2025 reached $606.2 million, up 7.57%, while the annual FY2025 figure was $606.2 million, 7.57% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $606.2 million at Amneal Pharmaceuticals, up from $563.5 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $606.2 million in Q4 2025 and troughed at $394.6 million in Q4 2021.
  • A 5-year average of $503.6 million and a median of $508.0 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: grew 18.79% in 2021 and later grew 7.57% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $394.6 million in 2021, then increased by 13.03% to $446.0 million in 2022, then grew by 13.91% to $508.0 million in 2023, then increased by 10.92% to $563.5 million in 2024, then rose by 7.57% to $606.2 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for AMRX at $606.2 million in Q4 2025, $563.5 million in Q4 2024, and $508.0 million in Q4 2023.